• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

    26.77 -0.03 (-0.11%)
    Streaming Delayed Price Updated: 2:45 PM EDT, May 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,711,647
    Open 26.81
    Bid (Size) 26.76 (4,600)
    Ask (Size) 26.77 (11,600)
    Prev. Close 26.80
    Today's Range 26.75 - 26.82
    52wk Range 9.830 - 26.85
    Shares Outstanding 34,233,643
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC is Investigating Whether KALV, THR, CECO are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire

    Performance

    YTD
    +73.2%
    +73.2%
    1 Month
    +36.7%
    +36.7%
    3 Month
    +72.6%
    +72.6%
    6 Month
    +100.7%
    +100.7%
    1 Year
    +130.0%
    +130.0%

    More News

    Read More
    Unusual volume stocks in Wednesday's session ↗
    Via Chartmill
    News headline image
    KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Unusual volume stocks are being observed in Thursday's session. ↗
    Via Chartmill
    News headline image
    Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement ↗
    Via The Motley Fool
    Topics Stocks
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are moving on Wednesday? ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
    Via Chartmill
    News headline image
    KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
    KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
    What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
    The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 26.77
    When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 05/14/26 02:45 PM ET
    What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 916.43M
    How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
    KalVista Pharmaceuticals, Inc. - Common Stock has 916M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.